<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23281" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hypophosphatemia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharma</surname>
            <given-names>Sandeep</given-names>
          </name>
          <aff>Mery Fitzgerald Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hashmi</surname>
            <given-names>Muhammad F.</given-names>
          </name>
          <aff>National Health Service</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kaur</surname>
            <given-names>Jasleen</given-names>
          </name>
          <aff>HealthPartners, Minneapolis</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Castro</surname>
            <given-names>Danny</given-names>
          </name>
          <aff>Baylor College of Med &#x00026; TX Children Hosp</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sandeep Sharma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Hashmi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jasleen Kaur declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Danny Castro declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23281.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Given its widespread role in nearly every molecular and cellular function, aberrations in serum phosphate levels can be highly impactful. Hypophosphatemia is defined as an adult serum phosphate level of fewer than 2.5 milligrams per deciliter (mg/dL). Normal serum phosphate levels in children are considerably higher, 4 to 7 mg/dL. Hypophosphatemia is a relatively common laboratory abnormality and is often an incidental finding. Severe hypophosphatemia can lead to significant clinical consequences and a possible increased mortality risk. Primary locations for regulation are the musculoskeletal, gastrointestinal, and renal systems, and comprehending the regulating factors is important for appropriate treatment. Phosphate metabolism is closely linked to calcium, and understanding the interplay among parathyroid hormone, vitamin D, and FGF23 is paramount. This activity describes the risk factors, evaluation, and management of hypophosphatemia and highlights the role of the interprofessional team in enhancing care delivery for affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Screen high-risk patient populations for hypophosphatemia, such as those with gastrointestinal malabsorption or renal disorders.</p></list-item><list-item><p>Apply knowledge of phosphate and calcium metabolism to tailor treatment and prevent related complications.</p></list-item><list-item><p>Select appropriate phosphate replacement therapies and dosage regimens based on individual patient needs.</p></list-item><list-item><p>Coordinate care within various specialties in the interprofessional team to enhance the delivery of comprehensive care for patients with hypophosphatemia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23281&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23281">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23281.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Phosphate is one of the most important molecular elements to normal cellular functions within the body.<xref ref-type="bibr" rid="article-23281.r1">[1]</xref>&#x000a0;It acts as an integral component of nucleic acids and is used to replicate DNA and RNA.<xref ref-type="bibr" rid="article-23281.r2">[2]</xref>&#x000a0;It is an energy source for molecular functions through its role in adenosine triphosphate (ATP).<xref ref-type="bibr" rid="article-23281.r2">[2]</xref><xref ref-type="bibr" rid="article-23281.r3">[3]</xref>&#x000a0;It incorporates into the phospholipids of cell membranes. It adds and deletes phosphate groups to or from proteins and functions as an on/off switch to regulate molecular activity.<xref ref-type="bibr" rid="article-23281.r3">[3]</xref>&#x000a0;Given its widespread role in nearly every molecular and cellular function, aberrations in serum phosphate levels can be highly impactful.&#x000a0; &#x000a0;&#x000a0;</p>
        <p>Hypophosphatemia is defined as an adult serum phosphate level of less than 2.5 mg/dL.<xref ref-type="bibr" rid="article-23281.r4">[4]</xref>&#x000a0;The normal serum phosphate level in children is considerably higher, between 4.0 to 7.0 mg/dL for children<italic toggle="yes">.</italic><xref ref-type="bibr" rid="article-23281.r5">[5]</xref> Hypophosphatemia is a relatively common laboratory abnormality and is often found incidentally.<xref ref-type="bibr" rid="article-23281.r6">[6]</xref><xref ref-type="bibr" rid="article-23281.r7">[7]</xref><xref ref-type="bibr" rid="article-23281.r8">[8]</xref><xref ref-type="bibr" rid="article-23281.r9">[9]</xref>&#x000a0;About 85% of phosphorus is found in bones and teeth, 14% intracellularly, and 1% in the serum/extracellular fluid component.&#x000a0;Free phosphate within the body is predominantly intracellular.<xref ref-type="bibr" rid="article-23281.r10">[10]</xref></p>
        <p>
<bold>Phosphorus Homeostasis</bold>
</p>
        <p>In general, phosphate levels increase through upregulated absorption in the intestines and decrease through renal excretion. Excess is stored in the bones, which act as a buffer to maintain a relatively stable total body content. A typical, nutritious diet provides 1000 to 2000 mg of phosphate daily.<xref ref-type="bibr" rid="article-23281.r11">[11]</xref><xref ref-type="bibr" rid="article-23281.r12">[12]</xref>&#x000a0;Of this, 600 mg&#x000a0;to 1200 mg is absorbed via the intestines.<xref ref-type="bibr" rid="article-23281.r13">[13]</xref>&#x000a0;Phosphate exists primarily in the crystallized extracellular matrix of bones, where it is relatively stable and inert. In the absence of pathology, the homeostasis of bone phosphate is neutral, with resorption and deposition of approximately 3 mg/kg per day.<xref ref-type="bibr" rid="article-23281.r14">[14]</xref>&#x000a0;Bone homeostasis of phosphate is regulated primarily by the parathyroid hormone, vitamin D, and sex hormones. The serum phosphate levels are predominantly maintained by absorption via the kidneys, of which 70% to 80% occurs in the proximal convoluted tubule.<xref ref-type="bibr" rid="article-23281.r4">[4]</xref><xref ref-type="bibr" rid="article-23281.r15">[15]</xref>&#x000a0;Sodium-dependent phosphate type 2 (NaPi II) cotransporters in the proximal tubule are a primary site of regulation.&#x000a0;The three types of type II transporters are type IIa, type IIb, and type IIc. Type IIa and IIc transporters are expressed predominately in the kidney. Type IIb transporters are expressed in the small intestine and control the dietary uptake of phosphate.<xref ref-type="bibr" rid="article-23281.r15">[15]</xref><xref ref-type="bibr" rid="article-23281.r16">[16]</xref><xref ref-type="bibr" rid="article-23281.r17">[17]</xref></p>
        <p>Three important regulatory hormones central to phosphate regulation are:</p>
        <list list-type="order">
          <list-item>
            <p>Parathyroid hormone (PTH)<xref ref-type="bibr" rid="article-23281.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>1,25 dihydroxy vitamin D3 (1,25D)</p>
          </list-item>
          <list-item>
            <p>FGF23 (Fibroblast growth factor 23)</p>
          </list-item>
        </list>
        <p>The role of each of these hormones on phosphate metabolism is complex (Figure 1: Phosphate Homeostasis) and incompletely understood. Phosphate regulation is intricately connected to calcium metabolism through regulation by these three important hormones.</p>
      </sec>
      <sec id="article-23281.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Hypophosphatemia most commonly occurs by one of the following three mechanisms (table 1):</p>
        <list list-type="bullet">
          <list-item>
            <p>Inadequate intestinal phosphate absorption</p>
          </list-item>
          <list-item>
            <p>Increased phosphate excretion</p>
          </list-item>
          <list-item>
            <p>Shift from extracellular phosphate into the intracellular space or into the mineral space of the&#x000a0;bone.</p>
          </list-item>
        </list>
        <table-wrap id="article-23281.table0" position="float" orientation="portrait">
          <table style="height: 2010px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 173.775px;" rowspan="1" colspan="1">
<bold>Causes of hypophosphatemia</bold>
</td>
                <td style="width: 162.05px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 172.575px;" rowspan="1" colspan="1">&#x000a0;</td>
              </tr>
              <tr>
                <td style="width: 173.775px;" rowspan="1" colspan="1">
<bold>Increased phosphate excretion&#x000a0;&#x000a0;</bold>
</td>
                <td style="width: 162.05px;" rowspan="1" colspan="1">PTH dependent</td>
                <td style="width: 172.575px;" rowspan="1" colspan="1">
<p>Primary hyperparathyroidism</p>
<p>Secondary hyperparathyroidism</p>
<p>Vitamin D deficiency</p>
</td>
              </tr>
              <tr>
                <td style="width: 173.775px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 162.05px;" rowspan="1" colspan="1">FGF23 dependent&#x000a0;<xref ref-type="bibr" rid="article-23281.r18">[18]</xref></td>
                <td style="width: 172.575px;" rowspan="1" colspan="1">
<p>X-linked hypophosphatemic rickets (XLH)</p>
<p>Autosomal dominant hypophosphatemic rickets (ADHR)</p>
<p>Autosomal recessive hypophosphatemic rickets (ARHR)</p>
<p>Tumor-induced osteomalacia (TIO) seen in mesenchymal tumors&#x000a0;</p>
<p>Fibrous dysplasia (FD)/McCune Albright Syndrome (MAS)</p>
<p>Neurofibromatosis (NF)</p>
<p>Hypophosphatemic rickets and hyperparathyroidism (HRHPT)</p>
</td>
              </tr>
              <tr>
                <td style="width: 173.775px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 162.05px;" rowspan="1" colspan="1">Intrinsic renal causes</td>
                <td style="width: 172.575px;" rowspan="1" colspan="1">
<p>Fanconi syndrome</p>
<p>Acute kidney injury</p>
<p>Recovery from acute tubular necrosis</p>
<p>Renal transplant</p>
<p>Sodium-phosphate cotransporter mutations&#x000a0;</p>
</td>
              </tr>
              <tr>
                <td style="width: 173.775px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 162.05px;" rowspan="1" colspan="1">Drugs&#x000a0;<xref ref-type="bibr" rid="article-23281.r19">[19]</xref><xref ref-type="bibr" rid="article-23281.r20">[20]</xref><xref ref-type="bibr" rid="article-23281.r21">[21]</xref></td>
                <td style="width: 172.575px;" rowspan="1" colspan="1">
<p>Diuretics</p>
<p>Corticosteroids</p>
<p>Carbonic anhydrase inhibitors</p>
<p>Bisphosphonates</p>
<p>Estrogen</p>
<p>Acyclovir</p>
<p>Imatinib</p>
<p>Denosumab&#x000a0;</p>
</td>
              </tr>
              <tr>
                <td style="width: 173.775px;" rowspan="1" colspan="1"><bold>Inadequate intestinal phosphate absorption</bold>&#x000a0;&#x000a0;</td>
                <td style="width: 162.05px;" rowspan="1" colspan="1">Decreased intake</td>
                <td style="width: 172.575px;" rowspan="1" colspan="1">
<p>Malnutrition</p>
<p>Alcoholism</p>
</td>
              </tr>
              <tr>
                <td style="width: 173.775px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 162.05px;" rowspan="1" colspan="1">Malabsorption</td>
                <td style="width: 172.575px;" rowspan="1" colspan="1">
<p>Bariatric surgery</p>
<p>Crohn&#x02019;s disease</p>
<p>Chronic diarrhea</p>
</td>
              </tr>
              <tr>
                <td style="width: 173.775px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 162.05px;" rowspan="1" colspan="1">Drugs&#x000a0;<xref ref-type="bibr" rid="article-23281.r19">[19]</xref></td>
                <td style="width: 172.575px;" rowspan="1" colspan="1">
<p>Phosphate&#x02013;binding antacids and binders</p>
</td>
              </tr>
              <tr>
                <td style="width: 173.775px;" rowspan="1" colspan="1">
<bold>Redistribution</bold>
</td>
                <td style="width: 162.05px;" rowspan="1" colspan="1">Intracellular shift</td>
                <td style="width: 172.575px;" rowspan="1" colspan="1">
<p>Respiratory alkalosis</p>
<p>Refeeding syndrome</p>
<p>Insulin therapy for hyperglycemia</p>
<p>Intravenous glucose therapy</p>
<p>Catecholamines (epinephrine, albuterol, terbutaline, dopamine)</p>
<p>Thyrotoxic periodic paralysis</p>
</td>
              </tr>
              <tr>
                <td style="width: 173.775px;" rowspan="1" colspan="1">
<bold>Shift into the bone matrix</bold>
</td>
                <td style="width: 162.05px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 172.575px;" rowspan="1" colspan="1">
<p>Post-parathyroidectomy (Hungry bone syndrome)</p>
<p>Use of cinacalcet for hyperparathyroidism&#x000a0;<xref ref-type="bibr" rid="article-23281.r22">[22]</xref></p>
</td>
              </tr>
              <tr>
                <td style="width: 173.775px;" rowspan="1" colspan="1">
<bold>Other drugs&#x000a0;</bold>
<xref ref-type="bibr" rid="article-23281.r19">[19]</xref>
</td>
                <td style="width: 162.05px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 172.575px;" rowspan="1" colspan="1">
<p>Alcohol (induced metabolic acidosis)</p>
<p>Phenytoin, phenobarbital (causing vitamin D deficiency or resistance)</p>
<p>Intravenous iron&#x000a0;</p>
<p>Acetaminophen poisoning</p>
</td>
              </tr>
              <tr>
                <td style="width: 173.775px;" rowspan="1" colspan="1">
<bold>Other causes</bold>
</td>
                <td style="width: 162.05px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 172.575px;" rowspan="1" colspan="1">
<p>Diabetic ketoacidosis</p>
<p>Poorly controlled diabetes</p>
<p>Renal replacement therapy</p>
<p>Prolonged fasting</p>
<p>Partial hepatectomy (affecting Vitamin D-25 hydroxylation)</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>PTH: Parathyroid hormone. FGF23: Fibroblast growth factor.</p>
      </sec>
      <sec id="article-23281.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Hypophosphatemia is typically asymptomatic, so it is difficult to estimate prevalence in the general population. However, 2.2%&#x02013;3.1% of hospitalized patients and 29%&#x02013;34% of ICU patients are documented with this condition.<xref ref-type="bibr" rid="article-23281.r23">[23]</xref>&#x000a0;It is much more prevalent in alcoholism, diabetic ketoacidosis, or sepsis, with a frequency of up to 80%.<xref ref-type="bibr" rid="article-23281.r24">[24]</xref><xref ref-type="bibr" rid="article-23281.r25">[25]</xref><xref ref-type="bibr" rid="article-23281.r26">[26]</xref>&#x000a0;The presence of severe hypophosphatemia is associated with increased mortality by almost four-fold.<xref ref-type="bibr" rid="article-23281.r27">[27]</xref>&#x000a0;The morbidity of hypophosphatemia is highly dependent on its etiology and severity.</p>
      </sec>
      <sec id="article-23281.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Hypophosphatemia's most common causes are inadequate phosphate absorption, increased phosphate excretion, and a shift from extracellular phosphate into intracellular space.<xref ref-type="bibr" rid="article-23281.r28">[28]</xref><xref ref-type="bibr" rid="article-23281.r29">[29]</xref><xref ref-type="bibr" rid="article-23281.r30">[30]</xref></p>
        <p>
<bold>Inadequate Intake</bold>
</p>
        <p>Hypophosphatemia secondary to inadequate phosphate intake occurs in the setting of prolonged poor phosphate dietary phosphate sources, intestinal malabsorption, and intestinal binding by exogenous agents.&#x000a0; Almost all diet types contain a surplus of phosphate sufficient to maintain needs. Additionally, renal adaptations typically can compensate for short-term deficiency.</p>
        <p>
<bold>Gastrointestinal Loss</bold>
</p>
        <p>Activated vitamin D (1,25D) is crucial to intestinal absorption of both calcium and phosphorus. Conditions associated with decreased 1,25D include chronic kidney disease (CKD), hepatic dysfunction, and hypercalcemia. Intestinal malabsorption may be due to a variety of causes. Notably, chronic diarrhea has been shown to increase phosphate losses. Certain medications, such as antacids containing aluminum, magnesium, and calcium, are known to bind with phosphate, decreasing the available free ion form by creating non-absorbable phosphate salts. Phosphate binders are also used in CKD to decrease the ever-present hyperphosphatemia, but overuse can lead to low phosphorus.&#x000a0;</p>
        <p>
<bold>Renal Loss</bold>
</p>
        <p>Increased excretion of phosphate occurs primarily in the renal system. The proximal renal tubule normally reabsorbs about 70% to 80% of filtered phosphate, and the distal tubule reabsorbs about 15% of filtered phosphate.<xref ref-type="bibr" rid="article-23281.r15">[15]</xref>&#x000a0;Phosphate reabsorption is stimulated by low serum phosphate concentration, which directly triggers the sodium-phosphate cotransporters of the proximal tubule and increases the expression and formation of new sodium-phosphate cotransporters. Conversely, the parathyroid hormone increases phosphate excretion by inhibiting the activity of sodium-phosphate cotransporters.</p>
        <p>FGF23, along with its cofactor Klotho, decreases the expression of sodium-phosphorus cotransporter 2 in the proximal tubule. Osteocytes secrete FGF23 in response to increased phosphorus and 1,25D; FGF23 also reduces 1,25D and PTH levels. FGF23 is highly linked to CKD progression, left ventricular hypertrophy, and cardiovascular disease, and levels are increased prior to detectable abnormalities of serum phosphate or PTH. Therefore, FGF23 may be a more sensitive early test for these conditions than either abnormal phosphorus or PTH.<xref ref-type="bibr" rid="article-23281.r31">[31]</xref><xref ref-type="bibr" rid="article-23281.r32">[32]</xref><xref ref-type="bibr" rid="article-23281.r33">[33]</xref>&#x000a0;To a much lesser degree, fibroblast growth factor 7, extracellular matrix phosphoglycoprotein, and secreted frizzled-related protein-4 are also associated with phosphaturia.<xref ref-type="bibr" rid="article-23281.r34">[34]</xref> Classic examples of increased FGF23 activity are&#x000a0;X-linked hypophosphatemic rickets (XLH) and tumor-induced osteomalacia (TIO). XLH is an inherited form of rickets associated with mutations in the PHEX gene. TIO is an acquired paraneoplastic condition leading to overproduction of FGF23.<xref ref-type="bibr" rid="article-23281.r10">[10]</xref></p>
        <p>Primary renal phosphate-wasting syndromes also exist related to structural tubular abnormalities causing defects in the sodium-phosphate cotransporter or defects in general proximal tubular reabsorption causing renal wasting of electrolytes and other substances.</p>
        <list list-type="bullet">
          <list-item>
            <p>Mutations in the sodium-phosphate cotransporter gene SLC34A3 cause type 2c sodium-phosphate cotransporter failure, and mutations in the SLC34A1 gene cause defective type 2a sodium-phosphate cotransporters.<xref ref-type="bibr" rid="article-23281.r35">[35]</xref></p>
          </list-item>
          <list-item>
            <p>The sodium-hydrogen exchanger regulatory factor 1&#x000a0;creates the sodium gradient, which powers most ion reabsorption. Mutations in this lead to losses of many ions and substances, including phosphate.<xref ref-type="bibr" rid="article-23281.r36">[36]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Fanconi syndrome is another classic cause of renal loss.<xref ref-type="bibr" rid="article-23281.r37">[37]</xref>&#x000a0;It is a generalized impairment in proximal tubular function leading to urinary wasting. Often, this is due to medications, hereditary conditions, or illnesses, such as multiple myeloma (where immunoglobulin light chains induce renal tubular damage) or Wilson disease (associated with copper accumulation in tubules.)<xref ref-type="bibr" rid="article-23281.r38">[38]</xref><xref ref-type="bibr" rid="article-23281.r39">[39]</xref><xref ref-type="bibr" rid="article-23281.r40">[40]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Polyuria also&#x000a0;will lead to obligate phosphate loss; causes include glucosuria, alcohol, lithium, diuretics, and rapid fluid volume expansion from oral or intravenous fluids.<xref ref-type="bibr" rid="article-23281.r19">[19]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Hyperparathyroidism</bold>
</p>
        <p>Primary and secondary hyperparathyroidism are common causes of hypophosphatemia in the outpatient setting. Primary hyperparathyroidism is due to an increased production of PTH from a parathyroid adenoma, resulting in hypercalcemia and hypophosphatemia. Secondary hyperparathyroidism&#x000a0;results from multiple other causes, including vitamin D deficiency, hypocalcemia, and chronic renal failure. PTH induces renal phosphate loss via the NaPi IIa co-transporter in the proximal tubule.<xref ref-type="bibr" rid="article-23281.r41">[41]</xref>&#x000a0;Secondary hyperparathyroidism has additional factors leading to low phosphate levels based on the underlying cause.</p>
        <p>
<bold>Redistribution</bold>
</p>
        <p>Intracellular shifting of phosphate stores may occur in a variety of clinical scenarios. Refeeding syndrome occurs when a patient who has been starved of nutrition (and depleted of total body phosphate) suddenly is replenished with carbohydrates, proteins, and lipids. The body begins to process the newfound foods to produce ATP for energy, and insulin and glucose help drive phosphate intracellularly.<xref ref-type="bibr" rid="article-23281.r42">[42]</xref>&#x000a0;Cells uptake all available free phosphate, leading to profound hypophosphatemia. In another redistribution physiology, hungry bone syndrome occurs after the correction of hyperparathyroidism, where osteopenic bones begin to reabsorb and store phosphate and calcium. This leads to increased bone demand for these ions and hypophosphatemia.<xref ref-type="bibr" rid="article-23281.r43">[43]</xref>&#x000a0;Acute respiratory alkalosis induces hypophosphatemia via changes in cellular pH. Increased pH stimulates phosphofructokinase, thus stimulating glycolysis to produce ATP, thus consuming phosphate from the cellular space. Serum phosphate is shifted intracellularly to meet this demand. While typically mild, extreme hyperventilation with subsequent PCO2 changes to less than 20 mmHg can lower phosphate concentrations to below 1 mg/dL (or 0.32 mmol/L). This is thought to be a common cause of marked hypophosphatemia in hospitalized patients.<xref ref-type="bibr" rid="article-23281.r44">[44]</xref><xref ref-type="bibr" rid="article-23281.r45">[45]</xref></p>
        <p>&#x000a0;<bold>End Stage Renal Disease</bold>&#x000a0;</p>
        <p>In patients with renal failure, hypophosphatemia can be seen as a result of dialysis therapy removing phosphate in bulk.<xref ref-type="bibr" rid="article-23281.r46">[46]</xref><xref ref-type="bibr" rid="article-23281.r47">[47]</xref>&#x000a0;Patients with renal transplants are also prone to hypophosphatemia due to a combination of hypercalcemia, hypophosphatemia, and tertiary hyperparathyroidism.<xref ref-type="bibr" rid="article-23281.r48">[48]</xref></p>
      </sec>
      <sec id="article-23281.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Most patients with hypophosphatemia are asymptomatic, and the most common symptom is generalized mild to moderate weakness. The history of presenting illness will sometimes indicate possible hypophosphatemia. Associated conditions include poor nutritional status, intestinal malabsorption, frequent or recurrent bone pain, bone fractures, history or suspicion of multiple myeloma, parenteral nutrition supplementation, diabetic ketoacidosis, and medication use&#x02014;including chronic glucocorticoids, antacids, cisplatin, or pamidronate.</p>
        <p>Clinical symptoms usually appear with moderate or severe hypophosphatemia. Neurologic symptoms include altered mental status, dysarthria, neurological instability including seizures, and focal neurologic findings such as numbness or reflexive weakness. Cardiac and respiratory failure can occur in severe cases. In addition to muscle weakness, muscle pain may signify hypophosphatemia-related rhabdomyolysis.<xref ref-type="bibr" rid="article-23281.r23">[23]</xref></p>
      </sec>
      <sec id="article-23281.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Hypophosphatemia is diagnosed with a simple serum measurement. It is important to remember that measured serum phosphate represents only 1% of total body phosphate, so small fluctuations can be a portent of serious depletion.</p>
        <p>Etiology is typically evident from history. However, if unknown, it is essential to determine renal phosphate excretion. Renal phosphate excretion can be measured either from a 24-hour urine collection or by calculation of the fractional excretion of filtered phosphate (FEPO4) from a random urine specimen. FEPO4 is calculated as follows&#x02014;where U represents urine values, and P represents plasma values of phosphate (PO4) and creatinine (Cr):</p>
        <list list-type="bullet">
          <list-item>
            <p>&#x000a0;FEPO4 = (UPO4 x&#x000a0;PCr&#x000a0;x 100) / (PPO4 x UCr)</p>
          </list-item>
        </list>
        <p>A 24-hour urine phosphate excretion of less than 100 mg or FEPO4 less than 5% shows decreased phosphate excretion, indicating hypophosphatemia is from a redistribution within the body or decreased intestinal absorption. A 24-hour urine phosphate excretion greater than 100 mg or FEPO4 greater than 5% indicates renal phosphate wasting. Hypophosphatemia in this scenario is likely due to hyperparathyroidism or vitamin D deficiency (Figure 2: Work-up of unexplained hypophosphatemia).</p>
      </sec>
      <sec id="article-23281.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The effects of hypophosphatemia are broad and impact nearly every system. Symptoms of this deficiency become apparent below 1 mg/dL (or 0.32 mmol/L).<xref ref-type="bibr" rid="article-23281.r49">[49]</xref><xref ref-type="bibr" rid="article-23281.r50">[50]</xref>&#x000a0;While symptoms are not clinically present in mild/moderate cases, it is essential to address and replace phosphate whenever abnormalities are noted. The appropriate regimen for replacement is determined depending on clinical symptoms.&#x000a0;&#x000a0;</p>
        <p>
<bold>Treatment of Hypophosphatemia with Oral Replacement Regimens&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Serum phosphorus &#x0003e;1.5 mg/dL: Total dose 1 mmol/kg (maximum 80 mmol) in 3-4 divided doses in 24 hours</p>
          </list-item>
          <list-item>
            <p>Serum phosphorus &#x0003c;1.5 mg/dL: Total dose 1.3 mmol/kg (maximum 100 mmol) in 3-4 divided doses in 24 hours</p>
          </list-item>
        </list>
        <p>Severe, symptomatic cases are appropriate for intravenous phosphate if the serum phosphate is less than 1 mg/dL (or 0.32 mmol/L) and should be changed to oral replacement when the serum phosphate exceeds 2 mg/dL (or 0.48 mmol/L). &#x000a0;Intravenous phosphate replacement can also be used in patients who cannot take oral medications or tolerate oral replacement.<xref ref-type="bibr" rid="article-23281.r51">[51]</xref></p>
        <p>
<bold>Treatment of Hypophosphatemia with Intravenous Replacement Regimens</bold>
</p>
        <p>Commonly used preparations: Sodium phosphate and potassium phosphate, containing equivalent phosphate content of 0.011 g/mL.</p>
        <list list-type="bullet">
          <list-item>
            <p>Serum phosphorus &#x0003c;1 mg/dL: 0.6 mmol/kg over 6 hours</p>
          </list-item>
          <list-item>
            <p>Serum phosphorus 1.0-1.7 mg/dL: 0.4 mmol/kg over 6 hours</p>
          </list-item>
          <list-item>
            <p>Serum phosphorus 1.7-2.2 mg/dL: 0.2 mmol/kg over 6 hours</p>
          </list-item>
        </list>
        <p>With renal dysfunction, the phosphate replacement dose should be reduced by 50%. In patients greater than 130% of their ideal body weight, adjusted body weight should be used to calculate the doses.<xref ref-type="bibr" rid="article-23281.r51">[51]</xref></p>
      </sec>
      <sec id="article-23281.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The most common manifestation is generalized weakness. As such, any other electrolyte aberrations should also be suspected, including hypokalemia, hypocalcemia and hypomagnesemia.&#x000a0;</p>
        <p>Additionally, the following conditions can mimic hypophosphatemia: benzodiazepine toxicity, delirium tremens, Guillain-Barre syndrome, hypothyroidism, hyperparathyroidism, insulin overdose, myopathies, primary muscle disorders, rhabdomyolysis, multiple myeloma, uremic encephalopathy.</p>
      </sec>
      <sec id="article-23281.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>A vast majority of the patients with hypophosphatemia have mild to moderate hypophosphatemia and will recover without complications. Even patients with severe hypophosphatemia can avoid complications if this condition is recognized early and the replacement of phosphate is promptly initiated. The presence of severe hypophosphatemia has been shown to be associated with significantly higher mortality rate in critically ill patients with sepsis or septic shock; whether this is due to hypophosphatemia alone or in combination with other factors remains to be determined.<xref ref-type="bibr" rid="article-23281.r52">[52]</xref><xref ref-type="bibr" rid="article-23281.r53">[53]</xref><xref ref-type="bibr" rid="article-23281.r54">[54]</xref></p>
      </sec>
      <sec id="article-23281.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Severe hypophosphatemia (&#x0003c;1 mg/dL) can be associated with a wide range of adverse clinical outcomes, especially if prolonged and there is a delay in management. The most significant effects are seen in the bones, but many other systems are also affected.</p>
        <p><bold>Bone:</bold> Prolonged hypophosphatemia leads to osteopenia, osteoporosis, rickets, or osteomalacia due to decreased bone mineralization and a resultant increase in bone fractures.<xref ref-type="bibr" rid="article-23281.r4">[4]</xref><xref ref-type="bibr" rid="article-23281.r55">[55]</xref>&#x000a0;Dental abnormalities such as periodontitis are also seen.<xref ref-type="bibr" rid="article-23281.r10">[10]</xref></p>
        <p><bold>Muscle:</bold>&#x000a0;Generalized muscular weakness can occur. Intracellular ATP depletion and mitochondrial dysfunction can cause rhabdomyolysis, resulting in renal injury and increased creatinine phosphokinases. This is especially pronounced in chronic hypophosphatemia, such as with alcohol use disorder.<xref ref-type="bibr" rid="article-23281.r56">[56]</xref><xref ref-type="bibr" rid="article-23281.r57">[57]</xref></p>
        <p><bold>Central Nervous System:</bold> The central nervous system may manifest with metabolic encephalopathy due to ATP depletion and may include an altered mental state, irritability, paresthesias, numbness, seizures, or coma.<xref ref-type="bibr" rid="article-23281.r58">[58]</xref><xref ref-type="bibr" rid="article-23281.r59">[59]</xref>&#x000a0;</p>
        <p><bold>Cardiac:</bold> Cardiac function is impacted by ATP depletion. The myocytes become less stable, and arrhythmias become more likely.<xref ref-type="bibr" rid="article-23281.r60">[60]</xref><xref ref-type="bibr" rid="article-23281.r61">[61]</xref>&#x000a0;Some studies show a significantly increased risk of heart failure, possibly related to lower levels of 2,3 DPG in erythrocytes and depleted ATP causing cardiomyopathy.<xref ref-type="bibr" rid="article-23281.r10">[10]</xref></p>
        <p><bold>Respiratory:</bold>&#x000a0;Respiratory depression is associated with hypophosphatemia.<xref ref-type="bibr" rid="article-23281.r62">[62]</xref>&#x000a0;Decreased diaphragmatic function impacts pulmonary function with subsequent hypoventilation. Ventilator-dependent patients are shown to have longer hospital courses and worse outcomes when hypophosphatemia is present.<xref ref-type="bibr" rid="article-23281.r62">[62]</xref><xref ref-type="bibr" rid="article-23281.r63">[63]</xref><xref ref-type="bibr" rid="article-23281.r64">[64]</xref></p>
        <p><bold>Gastrointestinal:</bold>&#x000a0;Dysfunction occurs as a result of ATP deficiency, with possible dysphagia, ileus, or constipation.<xref ref-type="bibr" rid="article-23281.r4">[4]</xref></p>
        <p><bold>Hematologic:</bold> Depletion of ATP within erythrocytes can impair oxygen-carrying ability and result in hemolytic anemia.&#x000a0;In addition, phosphorus is necessary for 2,3-diphosphoglycerate formation, facilitating oxygen release from hemoglobin.<xref ref-type="bibr" rid="article-23281.r65">[65]</xref><xref ref-type="bibr" rid="article-23281.r66">[66]</xref></p>
      </sec>
      <sec id="article-23281.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be instructed to keep track of their diet and water intake. A diet rich in phosphate should be encouraged, including dairy products, meat, poultry, and peanuts. They should follow up with the physician as advised or if any of these problems arise:</p>
        <list list-type="bullet">
          <list-item>
            <p>Confusion</p>
          </list-item>
          <list-item>
            <p>Irritable behavior</p>
          </list-item>
          <list-item>
            <p>Muscle pain</p>
          </list-item>
          <list-item>
            <p>Nausea, vomiting, or diarrhea</p>
          </list-item>
          <list-item>
            <p>Constipation lasting longer than&#x000a0;2&#x000a0;days</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23281.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <list list-type="bullet">
          <list-item>
            <p>The primary causes of hypophosphatemia are gastrointestinal malabsorption and increased renal excretion.</p>
          </list-item>
          <list-item>
            <p>The primary hormones involved are PTH, 1,25D, and FGF23 (with its cofactor Klotho).</p>
          </list-item>
          <list-item>
            <p>FGF23 is emerging as a significant predictor of cardiovascular mortality and CKD progression.</p>
          </list-item>
          <list-item>
            <p>FGF23 decreases expression of sodium phosphate cotransporters 2 (NaPi II) and downregulates PTH and 1,25D.</p>
          </list-item>
          <list-item>
            <p>In contrast, PTH increases expression of 1,25D.</p>
          </list-item>
          <list-item>
            <p>PTH is primarily regulated by serum calcium levels.</p>
          </list-item>
          <list-item>
            <p>Intestinal absorption of calcium and phosphorus is mediated by 1,25D.</p>
          </list-item>
          <list-item>
            <p>Hypophosphatemia can weaken the heart and respiratory muscles, leading to CHF and ventilator dependence.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23281.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Because of the diverse presentation of hypophosphatemia, this condition is best managed by an interprofessional team that consists of an internist, endocrinologist, intensivist, radiologist, and nephrologist, as needed. Pharmacists review oral and parenteral therapy, including dosage and drug compatibility. The effects of hypophosphatemia are broad and impact nearly every system. Symptoms of this deficiency become apparent below 1 mg/dL (or 0.32 mmol/L). In general, all symptomatic patients need treatment with phosphate; asymptomatic patients may be observed and monitored. &#x000a0;</p>
        <p>Providing patient-centered care for individuals with hypophosphatemia requires a collaborative effort among healthcare professionals, including physicians, advanced practice practitioners, nurses, pharmacists, and others. First and foremost, healthcare providers must possess the necessary clinical skills and expertise&#x000a0;when diagnosing, evaluating, and treating this condition. This includes proficiency in interpreting laboratory findings&#x000a0;and understanding the interplay among serum markers, urine electrolytes, and hormonal regulators. Moreover, a strategic approach involving evidence-based guidelines and individualized care plans tailored to each patient's unique circumstances is vital.</p>
        <p>Responsibilities within the interprofessional team should be clearly defined, with each member contributing their specialized knowledge and skills to optimize patient care. Effective interprofessional communication fosters a collaborative environment where information is shared, questions are encouraged, and concerns are addressed promptly.</p>
        <p>Lastly, care coordination is pivotal in ensuring seamless and efficient patient care. Physicians, advanced practitioners, nurses, pharmacists, and other healthcare professionals must work together to streamline the patient's journey, from diagnosis through treatment and follow-up. This coordination minimizes errors, reduces delays, and enhances patient safety, ultimately leading to improved outcomes and patient-centered care that prioritizes the well-being and satisfaction of those affected by hypophosphatemia.&#x000a0;The outlook for patients depends on the primary condition causing hypophosphatemia.&#x000a0;If the cause is benign, then treatment outcomes are excellent.</p>
      </sec>
      <sec id="article-23281.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23281&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23281">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/hypophosphatemia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23281">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23281/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23281">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-23281.s16">
        <fig id="article-23281.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Phosphate homeostasis. FGF23: fibroblast growth factor 23. PTH: parathyroid hormone. NaPi: Sodium phosphate co-transporter. Contributed by Dr. Jasleen Kaur. Generated using Biorender.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Untitled__x3x" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-23281.s17">
        <fig id="article-23281.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Work-up of unexplained hypophostatemia Contributed by Jasleen Kaur, MD. Generated using Biorender.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Untitled__x5x" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-23281.s18">
        <title>References</title>
        <ref id="article-23281.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takeda</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Taketani</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sawada</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The regulation and function of phosphate in the human body.</article-title>
            <source>Biofactors</source>
            <year>2004</year>
            <volume>21</volume>
            <issue>1-4</issue>
            <fpage>345</fpage>
            <page-range>345-55</page-range>
            <pub-id pub-id-type="pmid">15630224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peacock</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Phosphate Metabolism in Health and Disease.</article-title>
            <source>Calcif Tissue Int</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>108</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-15</page-range>
            <pub-id pub-id-type="pmid">32266417</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bonora</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Patergnani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rimessi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Marchi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Suski</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bononi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Giorgi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Missiroli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Poletti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wieckowski</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Pinton</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>ATP synthesis and storage.</article-title>
            <source>Purinergic Signal</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>343</fpage>
            <page-range>343-57</page-range>
            <pub-id pub-id-type="pmid">22528680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amanzadeh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reilly</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>Hypophosphatemia: an evidence-based approach to its clinical consequences and management.</article-title>
            <source>Nat Clin Pract Nephrol</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>136</fpage>
            <page-range>136-48</page-range>
            <pub-id pub-id-type="pmid">16932412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koljonen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Enlund-Cerullo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hauta-Alus</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Holmlund-Suila</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Valkama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rosendahl</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Andersson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pekkinen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>M&#x000e4;kitie</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Phosphate Concentrations and Modifying Factors in Healthy Children From 12 to 24 Months of Age.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2021</year>
            <month>Sep</month>
            <day>27</day>
            <volume>106</volume>
            <issue>10</issue>
            <fpage>2865</fpage>
            <page-range>2865-2875</page-range>
            <pub-id pub-id-type="pmid">34214153</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haider</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Lindner</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wolzt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Sauter</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Leichtle</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Fiedler</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Fuhrmann</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Exadaktylos</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Hyperphosphatemia Is an Independent Risk Factor for Mortality in Critically Ill Patients: Results from a Cross-Sectional Study.</article-title>
            <source>PLoS One</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>8</issue>
            <fpage>e0133426</fpage>
            <pub-id pub-id-type="pmid">26252874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>King</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Sica</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pierpaoli</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Severe hypophosphatemia in a general hospital population.</article-title>
            <source>South Med J</source>
            <year>1987</year>
            <month>Jul</month>
            <volume>80</volume>
            <issue>7</issue>
            <fpage>831</fpage>
            <page-range>831-5</page-range>
            <pub-id pub-id-type="pmid">3603104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berger</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Appelberg</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Reintam-Blaser</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ichai</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Joannes-Boyau</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Casaer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schaller</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Gunst</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Starkopf</surname>
                <given-names>J</given-names>
              </name>
              <collab>ESICM-MEN section</collab>
            </person-group>
            <article-title>Prevalence of hypophosphatemia in the ICU - Results of an international one-day point prevalence survey.</article-title>
            <source>Clin Nutr</source>
            <year>2021</year>
            <month>May</month>
            <volume>40</volume>
            <issue>5</issue>
            <fpage>3615</fpage>
            <page-range>3615-3621</page-range>
            <pub-id pub-id-type="pmid">33454128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Kou</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>Impact of hypophosphatemia on outcome of patients in intensive care unit: a retrospective cohort study.</article-title>
            <source>BMC Anesthesiol</source>
            <year>2019</year>
            <month>May</month>
            <day>24</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>86</fpage>
            <pub-id pub-id-type="pmid">31122196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rhee</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Elevated morbidity and mortality in patients with chronic idiopathic hypophosphatemia: a nationwide cohort study.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2023</year>
            <volume>14</volume>
            <fpage>1229750</fpage>
            <pub-id pub-id-type="pmid">37635983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uribarri</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Calvo</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Hidden sources of phosphorus in the typical American diet: does it matter in nephrology?</article-title>
            <source>Semin Dial</source>
            <year>2003</year>
            <season>May-Jun</season>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>186</fpage>
            <page-range>186-8</page-range>
            <pub-id pub-id-type="pmid">12753675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peacock</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Calcium metabolism in health and disease.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>5 Suppl 1</volume>
            <fpage>S23</fpage>
            <page-range>S23-30</page-range>
            <pub-id pub-id-type="pmid">20089499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stremke</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Hill Gallant</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Intestinal Phosphorus Absorption in Chronic Kidney Disease.</article-title>
            <source>Nutrients</source>
            <year>2018</year>
            <month>Sep</month>
            <day>23</day>
            <volume>10</volume>
            <issue>10</issue>
            <pub-id pub-id-type="pmid">30249044</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berndt</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Novel mechanisms in the regulation of phosphorus homeostasis.</article-title>
            <source>Physiology (Bethesda)</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>24</volume>
            <fpage>17</fpage>
            <page-range>17-25</page-range>
            <pub-id pub-id-type="pmid">19196648</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blaine</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chonchol</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Levi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Renal control of calcium, phosphate, and magnesium homeostasis.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2015</year>
            <month>Jul</month>
            <day>07</day>
            <volume>10</volume>
            <issue>7</issue>
            <fpage>1257</fpage>
            <page-range>1257-72</page-range>
            <pub-id pub-id-type="pmid">25287933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Segawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shiozaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kaneko</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Miyamoto</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The Role of Sodium-Dependent Phosphate Transporter in Phosphate Homeostasis.</article-title>
            <source>J Nutr Sci Vitaminol (Tokyo)</source>
            <year>2015</year>
            <volume>61 Suppl</volume>
            <fpage>S119</fpage>
            <page-range>S119-21</page-range>
            <pub-id pub-id-type="pmid">26598821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lederer</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Regulation of serum phosphate.</article-title>
            <source>J Physiol</source>
            <year>2014</year>
            <month>Sep</month>
            <day>15</day>
            <volume>592</volume>
            <issue>18</issue>
            <fpage>3985</fpage>
            <page-range>3985-95</page-range>
            <pub-id pub-id-type="pmid">24973411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>FGF23 and Phosphate Wasting Disorders.</article-title>
            <source>Bone Res</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>1</volume>
            <issue>2</issue>
            <fpage>120</fpage>
            <page-range>120-32</page-range>
            <pub-id pub-id-type="pmid">26273497</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liamis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Milionis</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Elisaf</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Medication-induced hypophosphatemia: a review.</article-title>
            <source>QJM</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>103</volume>
            <issue>7</issue>
            <fpage>449</fpage>
            <page-range>449-59</page-range>
            <pub-id pub-id-type="pmid">20356849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaur</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Chakrabarti</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Gambhir</surname>
                <given-names>IS</given-names>
              </name>
            </person-group>
            <article-title>Zoledronate Induced Hypocalcemia and Hypophosphatemia in Osteoporosis: A Cause of Concern.</article-title>
            <source>Curr Drug Saf</source>
            <year>2016</year>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>267</fpage>
            <page-range>267-9</page-range>
            <pub-id pub-id-type="pmid">27113952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clark</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Nystrom</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>A Case of Severe, Prolonged, Refractory Hypophosphatemia After Zoledronic Acid Administration.</article-title>
            <source>J Pharm Pract</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>172</fpage>
            <page-range>172-6</page-range>
            <pub-id pub-id-type="pmid">26739479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nowack</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wachtler</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Hypophosphatemia and hungry bone syndrome in a dialysis patient with secondary hyperparathyroidism treated with cinacalcet--proposal for an improved monitoring.</article-title>
            <source>Clin Lab</source>
            <year>2006</year>
            <volume>52</volume>
            <issue>11-12</issue>
            <fpage>583</fpage>
            <page-range>583-7</page-range>
            <pub-id pub-id-type="pmid">17175888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalantar-Zadeh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ganz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Trumbo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Seid</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Goodnough</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Parenteral iron therapy and phosphorus homeostasis: A review.</article-title>
            <source>Am J Hematol</source>
            <year>2021</year>
            <month>May</month>
            <day>01</day>
            <volume>96</volume>
            <issue>5</issue>
            <fpage>606</fpage>
            <page-range>606-616</page-range>
            <pub-id pub-id-type="pmid">33471363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Vaart</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Waanders</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>van Beek</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Vriesendorp</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Wolffenbutel</surname>
                <given-names>BHR</given-names>
              </name>
              <name>
                <surname>van Dijk</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Incidence and determinants of hypophosphatemia in diabetic ketoacidosis: an observational study.</article-title>
            <source>BMJ Open Diabetes Res Care</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>9</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">33597187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barak</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kalickman</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nisman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gurman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shoenfeld</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of hypophosphatemia in sepsis and infection: the role of cytokines.</article-title>
            <source>Am J Med</source>
            <year>1998</year>
            <month>Jan</month>
            <volume>104</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-7</page-range>
            <pub-id pub-id-type="pmid">9528718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaasbeek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Meinders</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Hypophosphatemia: an update on its etiology and treatment.</article-title>
            <source>Am J Med</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>118</volume>
            <issue>10</issue>
            <fpage>1094</fpage>
            <page-range>1094-101</page-range>
            <pub-id pub-id-type="pmid">16194637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Camp</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Allon</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Severe hypophosphatemia in hospitalized patients.</article-title>
            <source>Miner Electrolyte Metab</source>
            <year>1990</year>
            <volume>16</volume>
            <issue>6</issue>
            <fpage>365</fpage>
            <page-range>365-8</page-range>
            <pub-id pub-id-type="pmid">2089250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uday</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sakka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Randell</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Arya</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Brain</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tighe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Allgrove</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Arundel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pryce</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>H&#x000f6;gler</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Elemental formula associated hypophosphataemic rickets.</article-title>
            <source>Clin Nutr</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>38</volume>
            <issue>5</issue>
            <fpage>2246</fpage>
            <page-range>2246-2250</page-range>
            <pub-id pub-id-type="pmid">30314926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Christov</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>J&#x000fc;ppner</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Phosphate homeostasis disorders.</article-title>
            <source>Best Pract Res Clin Endocrinol Metab</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>685</fpage>
            <page-range>685-706</page-range>
            <pub-id pub-id-type="pmid">30449549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacquillet</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Unwin</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Physiological regulation of phosphate by vitamin D, parathyroid hormone (PTH) and phosphate (Pi).</article-title>
            <source>Pflugers Arch</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>471</volume>
            <issue>1</issue>
            <fpage>83</fpage>
            <page-range>83-98</page-range>
            <pub-id pub-id-type="pmid">30393837</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Isakova</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wahl</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vargas</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Guti&#x000e9;rrez</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Scialla</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Appleby</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nessel</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bellovich</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hamm</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gadegbeku</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Horwitz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Townsend</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Lash</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Leonard</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.</article-title>
            <source>Kidney Int</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>79</volume>
            <issue>12</issue>
            <fpage>1370</fpage>
            <page-range>1370-8</page-range>
            <pub-id pub-id-type="pmid">21389978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kurpas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Supe&#x00142;</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Idzikowska</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zieli&#x00144;ska</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>FGF23: A Review of Its Role in Mineral Metabolism and Renal and Cardiovascular Disease.</article-title>
            <source>Dis Markers</source>
            <year>2021</year>
            <volume>2021</volume>
            <fpage>8821292</fpage>
            <pub-id pub-id-type="pmid">34055103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guti&#x000e9;rrez</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Mannstadt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Isakova</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rauh-Hain</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Tamez</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Thadhani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>J&#x000fc;ppner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.</article-title>
            <source>N Engl J Med</source>
            <year>2008</year>
            <month>Aug</month>
            <day>07</day>
            <volume>359</volume>
            <issue>6</issue>
            <fpage>584</fpage>
            <page-range>584-92</page-range>
            <pub-id pub-id-type="pmid">18687639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prasad</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bhadauria</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Renal phosphate handling: Physiology.</article-title>
            <source>Indian J Endocrinol Metab</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>620</fpage>
            <page-range>620-7</page-range>
            <pub-id pub-id-type="pmid">23961477</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lederer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Miyamoto</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Clinical consequences of mutations in sodium phosphate cotransporters.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>7</volume>
            <issue>7</issue>
            <fpage>1179</fpage>
            <page-range>1179-87</page-range>
            <pub-id pub-id-type="pmid">22516291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>King</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nie</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Koo-McCoy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Minassian</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Jafri</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kohler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kumaraswamy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kozuka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Dragoli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rosenbaum</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Plain</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Greasley</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>J&#x000f6;nsson-Rylander</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Karlsson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Behrendt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Str&#x000f6;mstedt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ryden-Bergsten</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kn&#x000f6;pfel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pastor Arroyo</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Hernando</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Donowitz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Caldwell</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability.</article-title>
            <source>Sci Transl Med</source>
            <year>2018</year>
            <month>Aug</month>
            <day>29</day>
            <volume>10</volume>
            <issue>456</issue>
            <pub-id pub-id-type="pmid">30158152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ansermet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Moor</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Centeno</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Auberson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>DZ</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nikolaeva</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haenzi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Katanaeva</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gautschi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Katanaev</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rotman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Koesters</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schild</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pradervand</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bonny</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Firsov</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Renal Fanconi Syndrome and Hypophosphatemic Rickets in the Absence of Xenotropic and Polytropic Retroviral Receptor in the Nephron.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>1073</fpage>
            <page-range>1073-1078</page-range>
            <pub-id pub-id-type="pmid">27799484</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mandry</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Posner</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Tucci</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Eil</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Hyperphosphatemia in multiple myeloma due to a phosphate-binding immunoglobulin.</article-title>
            <source>Cancer</source>
            <year>1991</year>
            <month>Sep</month>
            <day>01</day>
            <volume>68</volume>
            <issue>5</issue>
            <fpage>1092</fpage>
            <page-range>1092-4</page-range>
            <pub-id pub-id-type="pmid">1913479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goyal</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>VB</given-names>
              </name>
            </person-group>
            <article-title>Wilson's Disease Presenting as Resistant Rickets.</article-title>
            <source>Gastroenterology Res</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-35</page-range>
            <pub-id pub-id-type="pmid">27957011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Subrahmanyam</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Vadivelan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Giridharan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Balamurugan</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Wilson's disease - A rare cause of renal tubular acidosis with metabolic bone disease.</article-title>
            <source>Indian J Nephrol</source>
            <year>2014</year>
            <month>May</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>171</fpage>
            <page-range>171-4</page-range>
            <pub-id pub-id-type="pmid">25120295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D&#x000e9;liot</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hernando</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Horst-Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Gisler</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Capuano</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Bacic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Biber</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Murer</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Parathyroid hormone treatment induces dissociation of type IIa Na+-P(i) cotransporter-Na+/H+ exchanger regulatory factor-1 complexes.</article-title>
            <source>Am J Physiol Cell Physiol</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>289</volume>
            <issue>1</issue>
            <fpage>C159</fpage>
            <page-range>C159-67</page-range>
            <pub-id pub-id-type="pmid">15788483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mehanna</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Moledina</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Travis</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Refeeding syndrome: what it is, and how to prevent and treat it.</article-title>
            <source>BMJ</source>
            <year>2008</year>
            <month>Jun</month>
            <day>28</day>
            <volume>336</volume>
            <issue>7659</issue>
            <fpage>1495</fpage>
            <page-range>1495-8</page-range>
            <pub-id pub-id-type="pmid">18583681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Witteveen</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>van Thiel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Romijn</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Hamdy</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>168</volume>
            <issue>3</issue>
            <fpage>R45</fpage>
            <page-range>R45-53</page-range>
            <pub-id pub-id-type="pmid">23152439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoppe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Metler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Berndt</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Knox</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Angielski</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Effect of respiratory alkalosis on renal phosphate excretion.</article-title>
            <source>Am J Physiol</source>
            <year>1982</year>
            <month>Nov</month>
            <volume>243</volume>
            <issue>5</issue>
            <fpage>F471</fpage>
            <page-range>F471-5</page-range>
            <pub-id pub-id-type="pmid">6291407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paleologos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Braude</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Persistent, progressive hypophosphataemia after voluntary hyperventilation.</article-title>
            <source>Clin Sci (Lond)</source>
            <year>2000</year>
            <month>May</month>
            <volume>98</volume>
            <issue>5</issue>
            <fpage>619</fpage>
            <page-range>619-25</page-range>
            <pub-id pub-id-type="pmid">10781395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tejeda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saffarian</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Uday</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dave</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Hypophosphatemia in end stage renal disease.</article-title>
            <source>Nephron</source>
            <year>1996</year>
            <volume>73</volume>
            <issue>4</issue>
            <fpage>674</fpage>
            <page-range>674-8</page-range>
            <pub-id pub-id-type="pmid">8856268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hendrix</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Hastings</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Samarin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>JQ</given-names>
              </name>
            </person-group>
            <article-title>Predictors of Hypophosphatemia and Outcomes during Continuous Renal Replacement Therapy.</article-title>
            <source>Blood Purif</source>
            <year>2020</year>
            <volume>49</volume>
            <issue>6</issue>
            <fpage>700</fpage>
            <page-range>700-707</page-range>
            <pub-id pub-id-type="pmid">32320987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torregrosa</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Cucchiari</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Bone Mineral Disease After Kidney Transplantation.</article-title>
            <source>Calcif Tissue Int</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>108</volume>
            <issue>4</issue>
            <fpage>551</fpage>
            <page-range>551-560</page-range>
            <pub-id pub-id-type="pmid">33765230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Halevy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bulvik</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Severe hypophosphatemia in hospitalized patients.</article-title>
            <source>Arch Intern Med</source>
            <year>1988</year>
            <month>Jan</month>
            <volume>148</volume>
            <issue>1</issue>
            <fpage>153</fpage>
            <page-range>153-5</page-range>
            <pub-id pub-id-type="pmid">3122679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lentz</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Kjellstrand</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Treatment of severe hypophosphatemia.</article-title>
            <source>Ann Intern Med</source>
            <year>1978</year>
            <month>Dec</month>
            <volume>89</volume>
            <issue>6</issue>
            <fpage>941</fpage>
            <page-range>941-4</page-range>
            <pub-id pub-id-type="pmid">102230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Felsenfeld</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>BS</given-names>
              </name>
            </person-group>
            <article-title>Approach to treatment of hypophosphatemia.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>60</volume>
            <issue>4</issue>
            <fpage>655</fpage>
            <page-range>655-61</page-range>
            <pub-id pub-id-type="pmid">22863286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al Harbi</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Al-Dorzi</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Al Meshari</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Tamim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Abdukahil</surname>
                <given-names>SAI</given-names>
              </name>
              <name>
                <surname>Sadat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arabi</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Association between phosphate disturbances and mortality among critically ill patients with sepsis or septic shock.</article-title>
            <source>BMC Pharmacol Toxicol</source>
            <year>2021</year>
            <month>May</month>
            <day>28</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <pub-id pub-id-type="pmid">34049590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shor</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Halabe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rishver</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tilis</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Matas</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Fux</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boaz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Severe hypophosphatemia in sepsis as a mortality predictor.</article-title>
            <source>Ann Clin Lab Sci</source>
            <year>2006</year>
            <season>Winter</season>
            <volume>36</volume>
            <issue>1</issue>
            <fpage>67</fpage>
            <page-range>67-72</page-range>
            <pub-id pub-id-type="pmid">16501239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Doepker</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Springer</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Exline</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>CV</given-names>
              </name>
            </person-group>
            <article-title>Impact of Serum Phosphate in Mechanically Ventilated Patients With Severe Sepsis and Septic Shock.</article-title>
            <source>J Intensive Care Med</source>
            <year>2020</year>
            <month>May</month>
            <volume>35</volume>
            <issue>5</issue>
            <fpage>485</fpage>
            <page-range>485-493</page-range>
            <pub-id pub-id-type="pmid">29519205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pri&#x000e9;</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Huart</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bakouh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Planelles</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dellis</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>G&#x000e9;rard</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hulin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Benqu&#x000e9;-Blanchet</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Silve</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Grandchamp</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Friedlander</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter.</article-title>
            <source>N Engl J Med</source>
            <year>2002</year>
            <month>Sep</month>
            <day>26</day>
            <volume>347</volume>
            <issue>13</issue>
            <fpage>983</fpage>
            <page-range>983-91</page-range>
            <pub-id pub-id-type="pmid">12324554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Funabiki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tatsukawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ashida</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Matsubara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kubota</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Uwatoko</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kitamura</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Disturbance of consciousness associated with hypophosphatemia in a chronically alcoholic patient.</article-title>
            <source>Intern Med</source>
            <year>1998</year>
            <month>Nov</month>
            <volume>37</volume>
            <issue>11</issue>
            <fpage>958</fpage>
            <page-range>958-61</page-range>
            <pub-id pub-id-type="pmid">9868960</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singhal</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Desroches</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gibbons</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mattana</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and predictors of rhabdomyolysis in patients with hypophosphatemia.</article-title>
            <source>Am J Med</source>
            <year>1992</year>
            <month>May</month>
            <volume>92</volume>
            <issue>5</issue>
            <fpage>458</fpage>
            <page-range>458-64</page-range>
            <pub-id pub-id-type="pmid">1580292</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Junge</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>[Acute polyneuropathy due to phosphate deficiency during parenteral feeding].</article-title>
            <source>Fortschr Med</source>
            <year>1979</year>
            <month>Feb</month>
            <day>22</day>
            <volume>97</volume>
            <issue>8</issue>
            <fpage>335</fpage>
            <page-range>335-8</page-range>
            <pub-id pub-id-type="pmid">105978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Imel</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Econs</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Approach to the hypophosphatemic patient.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>97</volume>
            <issue>3</issue>
            <fpage>696</fpage>
            <page-range>696-706</page-range>
            <pub-id pub-id-type="pmid">22392950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fuller</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Nichols</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Brenner</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Reversible depression in myocardial performance in dogs with experimental phosphorus deficiency.</article-title>
            <source>J Clin Invest</source>
            <year>1978</year>
            <month>Dec</month>
            <volume>62</volume>
            <issue>6</issue>
            <fpage>1194</fpage>
            <page-range>1194-1200</page-range>
            <pub-id pub-id-type="pmid">748374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davis</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Olichwier</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Chakko</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Reversible depression of myocardial performance in hypophosphatemia.</article-title>
            <source>Am J Med Sci</source>
            <year>1988</year>
            <month>Mar</month>
            <volume>295</volume>
            <issue>3</issue>
            <fpage>183</fpage>
            <page-range>183-7</page-range>
            <pub-id pub-id-type="pmid">3354591</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gravelyn</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Brophy</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Siegert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Peters-Golden</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Hypophosphatemia-associated respiratory muscle weakness in a general inpatient population.</article-title>
            <source>Am J Med</source>
            <year>1988</year>
            <month>May</month>
            <volume>84</volume>
            <issue>5</issue>
            <fpage>870</fpage>
            <page-range>870-6</page-range>
            <pub-id pub-id-type="pmid">3364446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>Effect of hypophosphatemia on the withdrawal of mechanical ventilation in patients with acute exacerbations of chronic obstructive pulmonary disease.</article-title>
            <source>Biomed Rep</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>413</fpage>
            <page-range>413-416</page-range>
            <pub-id pub-id-type="pmid">27073623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alsumrain</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Jawad</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Imran</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Riar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>DeBari</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Adelman</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Association of hypophosphatemia with failure-to-wean from mechanical ventilation.</article-title>
            <source>Ann Clin Lab Sci</source>
            <year>2010</year>
            <season>Spring</season>
            <volume>40</volume>
            <issue>2</issue>
            <fpage>144</fpage>
            <page-range>144-8</page-range>
            <pub-id pub-id-type="pmid">20421625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Altuntas</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Innice</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Basturk</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Seber</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Serin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ozturk</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Rhabdomyolysis and severe haemolytic anaemia, hepatic dysfunction and intestinal osteopathy due to hypophosphataemia in a patient after Billroth II gastrectomy.</article-title>
            <source>Eur J Gastroenterol Hepatol</source>
            <year>2002</year>
            <month>May</month>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>555</fpage>
            <page-range>555-7</page-range>
            <pub-id pub-id-type="pmid">11984155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23281.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Melvin</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Severe hypophosphatemia: a rare cause of intravascular hemolysis.</article-title>
            <source>Am J Hematol</source>
            <year>2002</year>
            <month>Mar</month>
            <volume>69</volume>
            <issue>3</issue>
            <fpage>223</fpage>
            <page-range>223-4</page-range>
            <pub-id pub-id-type="pmid">11891812</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
